SINTX strengthens antipathogenic patent portfolio with six US and three foreign patents in 2023

Sintx Technologies, Inc.

Granted six US patents in the last year covering silicon nitride applications: antifungals, antibacterial implants, SARS-CoV-2 inactivation, antiviral compositions, antipathogenic face masks.
Also received three foreign patents in 2023; 43 patent applications pending worldwide including in US, Asia, Europe, Brazil.
Patents support commercialization of silicon nitride in agriculture, dentistry, medical implants, durable medical equipment, and PPE.
NIH-funded commercialization work is ongoing based on coating and composite technologies covered by these patents.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.